Bone Biologics (BBLG) Operating Income (2014 - 2026)
Bone Biologics (BBLG) posted quarterly Operating Income of -$733105.0 for Q4 2025, up 52.85% year-over-year from -$479614.1 in Q4 2024, and down 2.49% quarter-over-quarter from -$715274.0 in Q3 2025.
Powered by 
Analysis
Bone Biologics (BBLG) Operating Income (2014 - 2026) Analysis & Trends
Bone Biologics (BBLG) has reported Operating Income for 12 consecutive years, with -$733105.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Operating Income rose 52.85% year-over-year to -$733105.0; the TTM figure through Dec 2025 stood at -$3.2 million (up 23.33% YoY), while the FY2025 annual figure was -$3.2 million, up 23.33% from the prior year.
- Operating Income declined to -$733105.0 in Q4 2025 per BBLG's latest filing, from -$715274.0 in the prior quarter.
- Across five years, Operating Income topped out at -$180924.0 in Q1 2021 and bottomed at -$3.1 million in Q1 2023.
- Historically, Operating Income has averaged -$1.1 million across 5 years, with a median of -$856600.5 in 2024.
- Annual changes were most pronounced in 2023 — Operating Income plunged 547.74% — and 2024, when it soared 73.37%.
- Bone Biologics' Operating Income stood at -$460482.0 in 2021, then tumbled by 179.51% to -$1.3 million in 2022, then increased by 9.87% to -$1.2 million in 2023, then tumbled by 34.05% to -$1.6 million in 2024, then surged by 52.85% to -$733105.0 in 2025.
- Business Quant data shows BBLG's Operating Income at -$733105.0 in Q4 2025, -$715274.0 in Q3 2025, and -$748075.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - | -505.13 Mn |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn | 325.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 133.12 Mn |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Bone Biologics | 1.00 Mn | 1.00 Mn | - | -808,106.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -808,106.00 |
| Dec 31, 2025 | -733,105.00 |
| Sep 30, 2025 | -715,274.00 |
| Jun 30, 2025 | -748,075.00 |
| Mar 31, 2025 | -1.04 Mn |
| Dec 31, 2024 | -1.55 Mn |
| Sep 30, 2024 | -951,021.00 |
| Jun 30, 2024 | -809,665.00 |
| Mar 31, 2024 | -903,536.00 |
| Dec 31, 2023 | -1.16 Mn |
| Sep 30, 2023 | -2.08 Mn |
| Jun 30, 2023 | -3.04 Mn |
| Mar 31, 2023 | -3.15 Mn |
| Dec 31, 2022 | -1.29 Mn |
| Sep 30, 2022 | -1.22 Mn |
| Jun 30, 2022 | -469,304.00 |
| Mar 31, 2022 | -689,499.00 |
| Dec 31, 2021 | -460,482.00 |
| Sep 30, 2021 | -229,789.00 |
| Jun 30, 2021 | -231,881.00 |